News

Robotic pancreatic resection safe in 250-patient series

View on the News

Robotic surgery is oversold and overdone

When it comes to robotic surgery, the emperor is not wearing any clothes. I don’t believe there has ever been a series that has conclusively shown that the robot has made any difference in patient outcomes or quality of the procedure. I believe that it is a technology that enables surgeons who cannot otherwise perform the procedure to perform the procedure. That’s been shown in the urology literature, particularly.

What’s going on in my community and others throughout the country is a terrible abuse of this technology, where we have doctors in our local hospitals taking out ovaries with this technology, taking out a uterus, and who are doing single-site robotic cholecystectomies in 4 hours at $4,000 in cost. They’re using robotic technology to do simple procedures that could otherwise be done better and faster without this technology.

We need to be outspoken and realistic about the use of robotic surgery. We need to advance this technology, but carefully and with a caveat.

Dr. Jeffrey L. Ponsky is professor and chairman of the department of surgery at Case Western Reserve University, Cleveland. He made his remarks as a discussant at the meeting.


 

AT THE ASA ANNUAL MEETING

He reported having received an honorarium from Medtronic on a single occasion for participation in a symposium on minimally invasive pancreatic surgery.

Pages

Recommended Reading

Designer T cells take aim at liver metastases
MDedge Hematology and Oncology
TML data on bevacizumab for colorectal cancer 'validate practice in the community'
MDedge Hematology and Oncology
What's in a name: Is the moniker 'palliative care' too loaded?
MDedge Hematology and Oncology
Dexamethasone eases end-of-life cancer-related fatigue
MDedge Hematology and Oncology
Adjuvant therapy selection in gastric cancer still more art than science
MDedge Hematology and Oncology
Radical resection trumps local excision in stage I CRC
MDedge Hematology and Oncology
Reflux after surgery increases risk of esophageal cancer
MDedge Hematology and Oncology
Index spots esophagectomy candidates at high risk for death
MDedge Hematology and Oncology
Esophagectomy cases rising steadily
MDedge Hematology and Oncology
Cardiorespiratory fitness predicts cancer risk, outcomes in men
MDedge Hematology and Oncology